Manatt Represents NeOnc in Multi-Million-Dollar PIPE Investment

A Manatt team led by Capital Markets Partner and Corporate and Finance Associate represented NeOnc Technologies Holdings, Inc. (NeOnc) in its strategic private investment in public equity (PIPE) deal.

This PIPE agreement involves the purchase and sale of up to 2,222,222 shares of common stock along with five‑year warrants, at a combined purchase price of $7.20 USD per share. The transaction is expected to generate up to $16 million USD in gross proceeds, with a leading $10 million USD investment from Cinctive Capital Management LP, an investment firm with a focus on biotechnology and therapeutics.

NeOnc is a clinical‑stage company developing treatments for brain and central nervous system diseases by creating therapies capable of successfully crossing the blood‑brain barrier. This partnership is positioned to accelerate NeOnc’s development of these therapies.

.